Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALX148, Rituximab, and Lenalidomide in B-Cell Non-Hodgkin Lymphoma
NCT05025800Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2021
- Primary completion
- Mar 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of evorpacept in B-cell non-Hodgkin lymphoma, sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2021; status: active, not recruiting.
02
Drugs
evorpacept
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05025800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05025800.